x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:15:00

Chemo Toxicity Prediction & Risk

OncoPharm ·

2022/03/17

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

en

00:17:10

Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)

OncoPharm ·

2022/03/10

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

en

00:12:09

7 + 3

OncoPharm ·

2022/03/03

The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3" 7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203

en

00:18:52

Prostate Ca Updates From ASCO GU 22

OncoPharm ·

2022/02/24

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

en

00:17:52

Bacillus Calmette-Guerin

OncoPharm ·

2022/02/17

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

en

00:21:52

KIR, HLA - C, & Rituximab

OncoPharm ·

2022/02/10

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis:

en

00:22:05

GI Cancer Updates & Tebentafusp

OncoPharm ·

2022/02/03

We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?

en

00:57:03

Precision Medicine Demystified

OncoPharm ·

2022/01/27

Dr. Howard McLeod joins the pod to talk Precision Medicine and the role pharmacists can play using pharmacogenomics and tumor genomics in cancer care. https://www.drhowardmcleod.com

en

00:18:42

New Hallmarks Of Cancers & LenPembro For Endometrial...

OncoPharm ·

2022/01/20

Topic covered include the latest updates to the seminal Hallmarks of Cancer work, adjuvant pembrolizumab for stage IIB/IIC melanoma, a prospective study of UGT1A1 testing, and Keynote-775. Hallmarks of Cancer: New Dimensions. https://cancerdiscovery.aacrjournals.org/content/12/1/31 UGT1A1 Genotype-guided dosing of irinotecan: https://doi.org/10.1016/j.ejca.2021.12.009 Keynote-775: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330

en

00:27:05

Carfilzomib

OncoPharm ·

2022/01/13

Foundations of OncoPharm: Carfilzomib (and a fair bit of bortezomib)

en

00:20:47

So, You Want to Work (from home) as a Specialty...

OncoPharm ·

2022/01/06

We're joined by Dr. Ryan McDade to hear about working as a Clinical Pharmacy Lead for Humana Specialty Pharmacy.

en

00:09:42

Drugs of 2021: Keep, Return Or Re-gift?

OncoPharm ·

2021/12/23

Happy Holidays!

en

00:28:23

ASH21 The More Things Change...

OncoPharm ·

2021/12/16

Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.

en

00:21:06

So, You Want to be a Pediatric Oncology Pharmacist

OncoPharm ·

2021/12/09

The 2nd episode in our Career Paths series features Dr. Morgan Randolph. She gives great insight into her role as pediatric oncology pharmacist and the choice between a PGY2 in Pediatrics or Oncology for those considering that decision.

en

00:20:25

Dasatinib Dosing & DREAMseq

OncoPharm ·

2021/12/02

Lots of updates to discuss from dasatinib dosing to ICI/TKI sequencing in BRAF-mutated metastatic melanoma to adjuvant chemo in node (+) breast cancer to some FDA approval updates.

en

00:13:43

Sun's Out, T Cells Out

OncoPharm ·

2021/11/18

Discussing one of the more intriguing studies of the year looking at whether metastatic melanoma survival is effected by what time of day immunotherapy is administered. Link: https://doi.org/10.1016/S1470-2045(21)00546-5

en

00:23:24

So, You Want To Be An MSL Oncology Pharmacist

OncoPharm ·

2021/11/11

What is a medical science liaison (MSL) and what do they do? Our 1st episode in a series highlighting different career options for oncology pharmacists featuring Dr. Christan Thomas.

en

00:19:22

Asciminib

OncoPharm ·

2021/11/04

Asciminib is now FDA approved and it's not just another TKI for CML

en

00:19:36

Adjuvant Atezo, Palbo-PPI Interaction? And More

OncoPharm ·

2021/10/28

From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode. Adjuvant atezolizumab for select NSCLC patients now FDA approved. 5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3 CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1 Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231

en

00:14:56

Decreased Cardiotoxicity With Infusional Doxorubicin

OncoPharm ·

2021/10/21

We return to our Landmarks of OncoPharm series to dive deep into an article that provided some of our foundational understanding of how anthracycline cardiotoxicity risk is influenced by rate of administration. Link: https://pubmed.ncbi.nlm.nih.gov/2910423/

en

423 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter